Gabather's clinical development with its lead compound GT-002 aims at a Proof-of-Concept (PoC) study addressing cognitive deficits in depression as the first indication. A single-dose target engagement study in healthy volunteers using electroencephalography (EEG) and the safety data acquired from the Multiple ascending dose study (MAD) will guide the design of this efficacy study in patients in an adaptive design. As the next step in this clinical development programme, company has submitted an application to the regulatory authorities in Portugal for the start of a double-blind, placebo controlled Multiple Ascending Doses (MAD) clinical trial in up to 24 healthy volunteers. This study primarily investigates the safety and tolerability of multiple escalating doses of GT-002. The pharmacokinetic properties of GT-002 upon repeated administration will also be investigated. Dosing of the healthy volunteers in the MAD study are expected to start as scheduled in First Quarter 2020. In parallel during the spring the target engagement study is planned to commence, followed by the start of PoC study in the latter part of 2020.